Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simethicone versus no bowel preparation during prostate radiotherapy
ACTRN12619000365167Phase 4Not yet recruiting
- Sponsor
- Sir Charles Gairdner Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of simethicone in prostate cancer (PCa) (2 arms), sponsored by Sir Charles Gairdner Hospital. Primary endpoint: Difference in mean rectal volume between study groups. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
simethicone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12619000365167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000365167.